WebFeb 18, 2024 · Financial Report - GUJARAT THEMIS BIOSYN LTD Here is a summary of financial information of GUJARAT THEMIS BIOSYN LTD for the financial year ending on 31 March, 2024. Revenue / turnover of GUJARAT THEMIS BIOSYN LTD is INR 1 cr - 100 cr Net worth of the company has increased by 45.87 % WebGujarat Themis Biosyn Limited is engaged in the manufacturing of pharmaceuticals and medicinal chemical products. The Company operates through manufacturing of bulk drugs segment. The Company's products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.

Gujarat Themis Biosyn Ltd. Share Price, Stock Analysis - StockEdge

WebMar 27, 2024 · BSE Announcements from Gujarat Themis Biosyn Ltd. ( See all) Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate - 10 hour (s) ago. Closure of Trading Window - 27 Mar 2024. WebMar 31, 2024 · Company Profile. Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants.The company has world-wide exports to satisfied customers, having customised … ingles spartanburg sc pine street

Gujarat Themis Biosyn Ltd share Price - ICICIdirect

Web4 hours ago · GUJARAT THEMIS BIOSYN LTD. - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate - Rediff MoneyWiz, the personal finance service … WebQuarterly & Annual Financial Results of Gujarat Themis Biosyn Ltd Check latest quarterly results and compare financial performance over past years. Get latest Standalone, … WebGujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 and it is engaged in manufacturing of APIs namely Rifamycin S and Rifamycin O. Rifamycin S is an intermediate for manufacturing drug Rifampicin (Antibiotic used for treatment of several mitsubishi outlander reset bluetooth